Lee Hambright
Stock Analyst at Bernstein
(0.4)
# 2007
Out of 5,234 analysts
19
Total ratings
71.43%
Success rate
9.28%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Medtronic | Maintains: Outperform | 96 97 | 79.75 | 21.63% | 2 | Nov 20, 2024 | |
Insulet | Initiates Coverage On: Outperform | 300 | 268.11 | 11.89% | 1 | Nov 6, 2024 | |
Tandem Diabetes Care | Initiates Coverage On: Outperform | 42 | 37.35 | 12.45% | 1 | Nov 6, 2024 | |
DexCom | Maintains: Outperform | 82 86 | 79.7 | 7.9% | 2 | Oct 25, 2024 | |
Boston Scientific | Maintains: Outperform | 92 100 | 91.2 | 9.65% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 133 138 | 112.86 | 22.28% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 350 365 | 541.98 | -32.65% | 2 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 136 152 | 103.56 | 46.77% | 1 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 183 | 143.4 | 27.62% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 288 295 | 361.38 | -18.37% | 2 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 132 135 | 73.55 | 83.55% | 2 | Mar 16, 2022 |